Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.

The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY(®) (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better recognize and manage diseases that have historically been overlooked or undertreated.